Presence or absence of intestinal metaplasia but not its burden is associated with prevalent high-grade dysplasia and cancer in Barrett's esophagus. Issue 8 (1st December 2014)

• Record Type: Journal Article
• Authors: Bansal, A.; McGregor, D. H.; Anand, O.; Singh, M.; Rao, D.; Cherian, R.; Wani, S. B.; Rastogi, A.; Singh, V.; House, J.; Jones, P. G.; Sharma, P.
• Is Part Of: Diseases of the esophagus. Volume 27:Issue 8(2014)
• Page Start: 751
• Page End: 756
• Publication Date: 2014-12-01
• Subjects: Barrett's esophagus -- columnar lined esophagus -- dysplasia -- esophageal adenocarcinoma -- goblet cell density -- intestinal metaplasia.; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1111/dote.12151
• Languages: English
• ISSNs: 1120-8694

Abstract

Summary: Universal agreement on the inclusion of intestinal metaplasia to diagnose B arrett's esophagus (BE ) is lacking. Our aim was to determine the association of intestinal metaplasia and its density with the prevalence of dysplasia/cancer in columnar lined esophagus (CLE ). Patients with CLE but no intestinal metaplasia (CLE -no IM ) were identified by querying the clinical pathology database using SNOMED codes for distal esophageal biopsies. CLE-IM patients were identified from a prospectively maintained database of BE patients. Subsequently, relative risks for prevalent dysplasia and cancer were calculated. Since patients with CLE -no IM are not usually enrolled in surveillance, only prevalent dysplasia/cancer on index endoscopy was analyzed. Goblet cell density and percent intestinal metaplasia were estimated. All biopsy slides were reviewed for dysplasia by two experienced gastrointestinal pathologists. Two hundred sixty-two CLE-IM and 260 CLE -no IM patients were included (age 64 ± 12 vs. 60 ± 11 years, P = 0.001; whites 92% vs. 82%, P = 0.001; males 99.7% vs. 99.3%, P = NS ; CLE length 3.4 ± 3.2 vears 1.4 ± 0.4 cm, P = 0.001 and hiatus hernia 64% vs. 56%, P = 0.013). The odds of finding low-grade dysplasia and of high-grade dysplasia (HGD )/cancer were 12.5-fold (2.9–53.8, P = 0.007) and 4.2-fold (95% CI 1.4–13, P = 0.01) higher, respectively, in the CLE-IM group. Reanalysis after controlling for important variables of age, race, and length did not significantly alter the overall results. In CLE-IM group, when patients with high (>50/LPF ) versus low goblet cell density (<50/LPF ) and <10% versus >10% intestinal metaplasia were compared, the odds of HGD /cancer, OR 1.5 (0.5–4.9, P = 0.5) and 1.97 (0.54–7.22), respectively, were not significantly higher. Demonstration of intestinal metaplasia continues to be an essential element in the definition of BE, but its quantification may not be useful for risk stratification of HGD /cancer in BE .